Navigation Links
Protein's role in regulating cell death sets direction for cancer research

A protein called calpain can be the key either preventing or promoting the cell death, a Queen's University study has found.

"This work provides proof in principle that pharmacological inhibition of calpain may be used to block cell death in situations where this is not desirable, such as in neuronal cells of Alzheimer's or Parkinson's patients, but to promote cell death in cancer cells where this is clearly a very desirable outcome," says lead researcher Peter Greer of two studies appearing in the Journal of Biological Chemistry (JBC).

Dr. Greer is a Professor of Pathology and Molecular Medicine with the Cancer Biology and Genetics division of Queen's University's Cancer Research Institute.

"All cells in our body have the ability to trigger an intrinsic programmed cell death response. In the case of nerve cells that have been temporarily cut off from their oxygen supply because of a stroke, or damaged by amyloid deposits, this might seem like a bad thing that could contribute to neurodegenerative disease," says Dr. Greer who produced the study with Yinfei Tan, Nathalie Dourdin, Chao Wu, Teresa De Veyra, and John S. Elce.

"On the other hand, when a cell's chromosomes are damaged by carcinogens or ultraviolet light in a way that could initiate cancer, this same programmed cell death response could save your life."

Supported by an operating grant from the Canadian Institute of Health Research the first study, published online and to appear in print on June 9, showed that calpain promoted programmed cell death after cells were damaged by chemicals that disrupt the endoplasmic reticulum, which is a major synthetic structure in the cell that controls the synthesis and distribution of new proteins.

In the second study, now published in JBC online, Dr. Greer and co-investigators Yinfei Tan, Chao Wu, and Teresa De Veyra, found that calpain also inhibits programmed cell death in response to other challenges, including some chemotherapeutic drugs.

This study showed that calpain contributes to the activation of AKT and JNK, two key players in the signaling pathways that control cellular responses to different death stimuli. These discoveries suggest that calpain inhibitors might improve the ability of chemotherapeutic drugs or radiation treatment to specifically kill tumour cells in cancer patients.


'"/>

Source:Queen's University


Related biology news :

1. A new mechanism of regulating RNA degradation
2. Depression gene may weaken mood-regulating circuit
3. Mechanism regulating tooth shape formulation found
4. Scientists discover new regulating mechanism in cells
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Enzyme allows B cells to resist death, leading to leukemia
7. Critical role in programmed cell death identified
8. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
9. The death of a very special chimpanzee
10. The very unexpected life and death of a leukemic cell
11. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... and GAITHERSBURG, Md. ... MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics ... of a definitive agreement for the merger of ... current investors include Novartis Venture Fund, HealthCap, Truffle ... be a fully-integrated and diversified immunotherapeutics company with ...
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... ... National Institutes of Health (NIH) to update its Data Sharing Policy. Specifically, the ... element of grant applications subject to the existing policy. AMIA recommended that NIH ...
(Date:1/19/2017)... Minneapolis, Minnesota (PRWEB) , ... January 19, 2017 ... ... contract research organization with services spanning the full spectrum of drug and device ... clinical research services to pharma/device companies and clinicians, today announced Verified Clinical ...
(Date:1/19/2017)... , Jan. 18, 2017 Acupath Laboratories, ... announces the formation of an Executive Committee that will ... beyond. John Cucci , a 15-year ... from Director of Business Development to Chief Sales ... Mr. Cucci served in senior sales leadership roles at ...
Breaking Biology Technology: